Herbal Monograph
Meadowsweet
Filipendula ulmaria (L.) Maxim.
Rosaceae (Rose family)
The original 'herbal aspirin' — a gentle yet powerful gastroprotective anti-inflammatory that soothes the stomach...
Overview
Plant Description
Filipendula ulmaria is a herbaceous perennial growing 60–120 cm tall with erect, reddish, angular stems. Leaves are pinnate with 2–5 pairs of toothed leaflets, dark green above and whitish-tomentose beneath, with a distinctive terminal leaflet larger than the laterals. The fragrant, creamy-white flowers are borne in dense, irregular cymes from June to September, producing a sweet, almond-honey scent. The small spirally twisted achene fruits are characteristic of the genus.
Habitat
Prefers damp to wet habitats including meadows, fens, marshes, ditches, stream banks, and moist woodland edges. Thrives in rich, mildly acidic to neutral soils with consistent moisture. Common in water meadows and flood plains at elevations up to 1,500 m.
Distribution
Native throughout Europe and western Asia, from the British Isles and Scandinavia east to Siberia and south to Turkey and Iran. Naturalized in parts of eastern North America. Particularly abundant in the British Isles, northern France, Germany, and Scandinavia.
Parts Used
Flowers (Filipendulae ulmariae flos)
Preferred: Dried flowers for infusion (most traditional and widely recommended); tincture of fresh or dried flowers; cold infusion
The flowers are the primary medicinal part, listed in the European Pharmacopoeia (Ph. Eur.) monograph, the German Commission E monograph, and the British Herbal Pharmacopoeia (BHP). The flowers contain the highest concentration of volatile salicylates (salicylaldehyde, methyl salicylate) as well as flavonoids (including the unique spiraeoside), tannins, and mucilage. The combination of salicylates with protective mucilage and tannins is considered therapeutically significant — the whole flower extract is gastroprotective despite containing salicylate precursors. The flowers are the part most responsible for the plant's characteristic sweet, almond-honey fragrance.
Flowering tops / aerial herb (Filipendulae ulmariae herba)
Preferred: Dried herb for infusion; tincture (1:5, 45% ethanol)
The European Pharmacopoeia monograph covers both the flowers (flos) and the herb (herba — the aerial parts including flowers, leaves, and upper stems). The herb is more commonly available commercially than isolated flowers. It contains all the same constituent classes as the flowers but with relatively higher tannin content from the leaves and stems. The ESCOP monograph and some traditional references specify the herb rather than the flowers alone. In practice, both are used interchangeably, though the flowers are considered the superior preparation for gastric indications.
Leaves (Filipendulae ulmariae folium)
Preferred: Dried leaf for infusion; combined with flowers in compound preparations
Leaves contain higher concentrations of ellagitannins (rugosins D and E) and somewhat lower volatile salicylate content compared to the flowers. The astringent tannins make the leaf particularly useful in formulations targeting diarrhea and intestinal inflammation. The leaves also contain significant flavonoid content (quercetin, kaempferol glycosides). In some traditional practices, the leaf is preferred for its astringent, anti-diarrheal action while the flower is preferred for its anti-inflammatory and antacid properties.
Root/rhizome (Filipendulae ulmariae radix)
Preferred: Decoction of dried root (historical); less commonly used today
The root and rhizome are less commonly used in modern practice but have a history of traditional use, particularly for febrile conditions and rheumatic complaints. Higher in tannins than the aerial parts. Some older herbals (e.g., Culpeper, Gerard) reference root preparations. The root is not covered by the current European Pharmacopoeia or Commission E monographs and is not the preferred part for contemporary practice.
Key Constituents
Salicylate compounds (phenolic glycosides and volatile salicylates)
The salicylate compounds collectively account for meadowsweet's anti-inflammatory, analgesic, antipyretic, and antirheumatic properties. Crucially, the whole-plant salicylate complex in meadowsweet behaves differently from isolated, synthesized acetylsalicylic acid (aspirin). While aspirin inhibits cyclooxygenase (COX) enzymes and suppresses prostaglandin synthesis — including the gastroprotective prostaglandins PGE2 and PGI2, leading to gastric erosion — meadowsweet's salicylates are accompanied by gastroprotective mucilage, astringent tannins, and anti-inflammatory flavonoids that PROTECT the gastric mucosa. This is the central pharmacological paradox of meadowsweet: it contains aspirin precursors yet protects the stomach rather than damaging it. The volatile salicylates (salicylaldehyde, methyl salicylate) are thermolabile and destroyed by boiling, which is why infusion (not decoction) is the correct preparation method.
Flavonoids
The flavonoid fraction of meadowsweet is therapeutically essential and synergistically enhances the salicylate-mediated anti-inflammatory effects. The unique spiraeoside (quercetin-4'-O-glucoside) serves both as a quality marker and as a significant contributor to anti-inflammatory and gastroprotective activity. The flavonoids provide complementary anti-inflammatory mechanisms (NF-kB inhibition, LOX inhibition, mast cell stabilization) that are distinct from the salicylate COX pathway. This multi-target anti-inflammatory activity is a key example of the 'network pharmacology' advantage of whole-plant preparations over isolated single compounds. The antioxidant activity of the flavonoid fraction (radical scavenging, metal chelation, enhanced endogenous antioxidant enzyme activity) further protects the gastric mucosa and contributes to the antirheumatic and cardioprotective effects.
Tannins (hydrolyzable tannins, specifically ellagitannins)
The ellagitannin fraction is responsible for meadowsweet's significant astringent action — binding and cross-linking mucosal surface proteins to form a protective barrier on inflamed gastrointestinal mucosa. This astringent action is therapeutically crucial: it underpins the anti-diarrheal use of the leaf, protects ulcerated or inflamed gastric and intestinal tissue, and — critically — is one of the mechanisms by which whole meadowsweet protects the stomach despite containing salicylate compounds. The tannins precipitate proteins on the mucosal surface, reducing permeability and creating a physical barrier against acid, pepsin, and irritants. Additionally, the ellagitannins provide potent antioxidant and antimicrobial activity. The tannin content is highest in the leaves and lowest in the flowers, which is why leaf-containing preparations (the herb, herba) have stronger astringent properties than flower-only preparations.
Mucilage and polysaccharides
The mucilage content is therapeutically essential to understanding why meadowsweet is gastroprotective rather than gastrotoxic despite containing salicylate precursors. The mucilaginous polysaccharides coat the gastric lining, providing a physical demulcent barrier. This, combined with the astringent tannins that protect the mucosal surface proteins and the anti-inflammatory flavonoids, creates a multi-layered gastroprotective system that MORE than counterbalances any potential gastric irritation from the salicylate content. This synergistic gastroprotection is a classic example of the superiority of whole-plant preparations over isolated active compounds.
Volatile oil (essential oil)
The volatile oil fraction is both the aromatic signature of meadowsweet and a therapeutically significant component. The volatile salicylates (salicylaldehyde, methyl salicylate) are rapidly absorbed and contribute to the anti-inflammatory, analgesic, and antipyretic actions. Their volatility mandates careful preparation technique — the insistence on infusion rather than decoction in all herbal pharmacopoeias and traditional references is directly related to preserving this fraction. Loss of the characteristic fragrance during preparation indicates destruction of volatile salicylates and reduced therapeutic potency.
Organic acids and vitamins
The organic acids contribute modestly to the overall pharmacological profile. Citric acid supports the diuretic and urinary antiseptic actions. Ascorbic acid contributes antioxidant and immune-supportive activity relevant to the traditional febrifuge use. Free and conjugated salicylic acid, while present in lower therapeutic quantities than in pharmaceutical aspirin, contributes to the cumulative anti-inflammatory and analgesic effect within the context of the whole-plant extract.
Phenolic acids and coumarins
The phenolic acid and coumarin fraction provides supplementary antioxidant and gastroprotective activity. Ellagic acid released from ellagitannins in the GI tract has been shown to protect gastric mucosa against ethanol- and NSAID-induced damage in animal models, providing yet another mechanism by which meadowsweet protects the stomach. The phenolic acid profile contributes to the overall high total polyphenol content of meadowsweet, which ranks among the highest of European medicinal herbs.
Herbal Actions
Reduces inflammation
The hallmark pharmacological action of meadowsweet and the basis of its reputation as 'herbal aspirin.' Anti-inflammatory activity is mediated through multiple complementary mechanisms: (1) Salicylate compounds (salicylaldehyde, methyl salicylate, salicin) are metabolized to salicylic acid, which inhibits cyclooxygenase (COX) and reduces prostaglandin synthesis; (2) Flavonoids (quercetin, spiraeoside) inhibit NF-kB activation, 5-lipoxygenase, and phospholipase A2, reducing leukotriene and pro-inflammatory cytokine production; (3) Ellagitannins (rugosins) demonstrate direct anti-inflammatory activity via inhibition of complement activation and free radical scavenging. Halkes et al. (1997) demonstrated that meadowsweet flower extract inhibits both COX-1 and COX-2, and also inhibits the complement system (both classical and alternative pathways) — providing a broader anti-inflammatory profile than aspirin alone. This multi-target anti-inflammatory activity — engaging COX, LOX, NF-kB, and complement pathways simultaneously — is characteristic of a whole-plant preparation and cannot be replicated by any single isolated constituent.
[1, 3, 8]The most remarkable and clinically significant pharmacological property of meadowsweet: despite containing salicylate precursors (compounds from which aspirin was derived), whole meadowsweet PROTECTS the gastric mucosa rather than damaging it. This paradox is explained by the synergistic gastroprotective matrix of the whole plant: (1) Mucilage forms a demulcent coating over the gastric lining, physically shielding it from acid and irritants; (2) Tannins (ellagitannins) create a protein-precipitate layer on the mucosal surface, reducing permeability and providing an astringent protective barrier; (3) Flavonoids (quercetin, spiraeoside) have direct cytoprotective effects on gastric mucosal cells and inhibit histamine-mediated acid secretion; (4) The salicylate content per dose is far lower than pharmaceutical aspirin, delivering anti-inflammatory benefit without sufficient COX-1 inhibition to compromise protective prostaglandin levels. Barnaulov & Denisenko (1980) demonstrated in animal models that meadowsweet flower extract reduced experimental gastric ulcer formation — the extract was ANTI-ulcer rather than pro-ulcer, despite its salicylate content. This finding supports centuries of traditional use for gastritis, heartburn, and peptic ulcer. The Commission E approved meadowsweet specifically as a supportive therapy for colds, citing its anti-inflammatory properties, and traditional European herbalism has long regarded it as the premier herbal medicine for hyperacidity and gastric inflammation.
[1, 2, 3, 7]Meadowsweet has a well-established traditional reputation as a herbal antacid — reducing gastric hyperacidity and relieving heartburn. The antacid action is multifactorial: the mucilage physically buffers acid contact with the mucosa, the tannins reduce mucosal permeability to acid, and the flavonoids may modulate acid secretion at the cellular level. Traditional British, German, and European herbalism considers meadowsweet one of the first-choice herbs for heartburn, acid reflux, and hyperacidity. The British Herbal Pharmacopoeia (1983) lists 'antacid' as a primary action. Unlike pharmaceutical antacids (which neutralize acid chemically) or proton pump inhibitors (which block acid production), meadowsweet's approach is primarily protective and soothing — it does not necessarily reduce acid production dramatically but rather protects the mucosa from acid damage and reduces acid-related symptoms.
[1, 2, 3]Tightens and tones tissue, reduces secretions
The high ellagitannin content (rugosins D and E, tellimagrandins) provides significant astringent activity — tightening and toning mucosal tissues, reducing secretions, and protecting inflamed surfaces. The astringent action is most pronounced in preparations that include the leaves (herba) rather than flowers alone, as tannin concentration is highest in the leaves. Therapeutically, this astringency underpins the anti-diarrheal action, contributes to the gastroprotective effect (mucosal protein precipitation), and supports the traditional use for excessive menstrual bleeding and other hemorrhagic conditions. The astringent tannins also provide local antimicrobial activity by denaturing microbial surface proteins.
[2, 3]Promotes perspiration
Meadowsweet is classified as a diaphoretic (sweat-promoting herb) in traditional European herbalism, used to promote perspiration during febrile illness to support the body's natural fever response. The diaphoretic action is attributed to the volatile salicylate compounds and the flavonoid content. Taken as a hot infusion, meadowsweet promotes peripheral vasodilation and sweating, supporting the resolution of fevers and upper respiratory infections. This is one of the oldest and most consistent traditional uses — meadowsweet was one of the standard 'fever herbs' of European folk medicine. The Commission E specifically approved meadowsweet as supportive therapy for colds.
[1, 3, 4]Meadowsweet has a long-established reputation for the relief of rheumatic and arthritic complaints, recorded in traditional herbals from the medieval period onward. The antirheumatic action combines anti-inflammatory (salicylates and flavonoids), analgesic (salicylates), and mild diuretic (promoting excretion of metabolic waste products) effects. The Commission E approved meadowsweet for 'supportive therapy of the common cold' but also recognized the traditional antirheumatic indication. The BHP lists meadowsweet specifically for 'rheumatic joint disease.' The salicylate content provides direct anti-inflammatory and analgesic benefit to inflamed joints, while the diuretic action supports the clearance of uric acid and metabolic waste from joint tissues.
[1, 2, 3]Meadowsweet is traditionally used in urinary tract support, classified by the Commission E as appropriate for 'flushing therapy' in urinary tract conditions. The mild diuretic effect promotes increased urine flow, helping to flush bacteria from the urinary tract. Salicylate metabolites excreted in the urine may contribute mild antiseptic activity in the urinary tract. The flavonoids (quercetin) have demonstrated antimicrobial activity against common urinary pathogens in vitro. This action is mild and meadowsweet is typically used as part of a combination formula for UTI support rather than as a standalone urinary antiseptic.
[1, 3]Mild pain-relieving activity mediated primarily by the salicylate compounds (metabolized to salicylic acid, which is a recognized analgesic agent). The analgesic potency of a meadowsweet infusion is considerably lower than that of pharmaceutical aspirin (a typical infusion provides far less salicylic acid equivalent than a 325-600 mg aspirin tablet), but the multi-compound anti-inflammatory action provides complementary pain relief through multiple pathways. Most useful for mild to moderate inflammatory pain (headache, joint pain, menstrual cramps) rather than acute severe pain. The analgesic action is enhanced when meadowsweet is combined with other anti-inflammatory or analgesic herbs in compound formulas.
[2, 3]Mild fever-reducing activity attributable to salicylate metabolism. Salicylic acid (the in vivo metabolite) acts centrally on the hypothalamic thermoregulatory center to reduce elevated body temperature. Combined with the diaphoretic action (promoting perspiration), meadowsweet supports natural fever management. The antipyretic effect is mild at standard herbal doses — much less potent than pharmaceutical aspirin or paracetamol, but consistent with the traditional approach of supporting the body's fever response rather than aggressively suppressing it.
[3, 4]Prevents or slows oxidative damage to cells
Meadowsweet demonstrates significant antioxidant activity attributable to its high total polyphenol content — particularly the flavonoids (quercetin, spiraeoside, rutin), ellagitannins (rugosins D and E), and phenolic acids (gallic acid, ellagic acid). Multiple in vitro studies have confirmed potent radical scavenging (DPPH, ABTS, superoxide), metal chelation, and lipid peroxidation inhibition. Samardzic et al. (2018) characterized the phenolic profile and confirmed high antioxidant capacity. The antioxidant activity contributes to the gastroprotective, anti-inflammatory, and antirheumatic effects by neutralizing reactive oxygen species at sites of inflammation and tissue damage.
[8, 9]Kills or inhibits the growth of microorganisms
Meadowsweet demonstrates mild to moderate antimicrobial activity in vitro, attributable primarily to the ellagitannin fraction (rugosins, tellimagrandins) and the volatile salicylates. Activity has been demonstrated against common gastrointestinal and urinary pathogens, including Helicobacter pylori (relevance to gastroprotective/anti-ulcer action), Staphylococcus aureus, Escherichia coli, and Candida albicans. The antimicrobial activity is not strong enough to classify meadowsweet as a primary antimicrobial herb, but it contributes meaningfully to its gastrointestinal and urinary tract actions.
[9]Therapeutic Indications
Digestive System
Heartburn, acid reflux, and gastroesophageal reflux disease (GERD)
The primary indication for meadowsweet and the one best supported by the convergence of traditional use, pharmacological rationale, and clinical experience. The Commission E approved meadowsweet as a supportive therapy, and the ESCOP monograph (2003) lists dyspeptic complaints as a primary indication. The BHP (1983) lists meadowsweet specifically for 'atonic dyspepsia with heartburn and hyperchlorhydria.' The gastroprotective mechanism is well-characterized: mucilage coats and soothes the esophageal and gastric mucosa; tannins create a protective astringent layer; flavonoids (spiraeoside, quercetin) provide cytoprotective and anti-inflammatory effects; the total salicylate load is sub-irritant and the anti-inflammatory effect outweighs any potential for gastric irritation. Barnaulov & Denisenko (1980) demonstrated anti-ulcer activity in vivo. Clinical experience across centuries of British and European herbal practice consistently identifies meadowsweet as a first-choice herb for heartburn and acid-related gastric discomfort.
[1, 2, 3, 7]Gastritis and gastric mucosal inflammation
Meadowsweet has a well-established traditional and pharmacological basis for treating gastric mucosal inflammation. The multi-mechanism gastroprotective action (mucilage coating, tannin astringency, flavonoid cytoprotection, anti-inflammatory salicylates) directly addresses the pathophysiology of gastritis. Barnaulov & Denisenko (1980) animal study demonstrated reduced gastric ulcer formation with meadowsweet extract. The ESCOP monograph includes 'gastric complaints' in the indication list. Traditional European herbalism (British, German, French) has continuously employed meadowsweet for gastritis for centuries.
[2, 3, 7]Peptic and duodenal ulcer (supportive, traditional)
Traditional use of meadowsweet for peptic and duodenal ulcers is long-standing, supported by the pharmacological rationale of mucosal protection and the Barnaulov & Denisenko (1980) anti-ulcer study. However, modern clinical trials specifically evaluating meadowsweet for peptic ulcer disease have not been conducted. Given the availability of effective pharmaceutical treatments (proton pump inhibitors, H. pylori eradication), meadowsweet is used as a supportive herb rather than a primary ulcer treatment. Its role is in mucosal protection, symptom relief, and supporting healing alongside appropriate medical management.
[3, 7]Hyperacidity and dyspepsia
Commission E-approved indication (as supportive therapy). The BHP (1983) specifically lists 'hyperchlorhydria' as an indication. Meadowsweet's antacid and gastroprotective actions address hyperacidity through mucosal protection and symptomatic relief rather than acid secretion suppression. Effective for functional dyspepsia characterized by upper abdominal discomfort, bloating, and acid-related symptoms. Best used as a simple infusion taken 20-30 minutes before or between meals.
[1, 2, 3]Diarrhea (acute and chronic, non-specific)
The astringent action of the ellagitannins (rugosins D and E) makes meadowsweet useful for non-specific diarrhea. The tannins reduce intestinal mucosal permeability and excess secretion, while the anti-inflammatory and antimicrobial actions address underlying mucosal inflammation and potential microbial drivers. Preparations that include the leaf (herba, which has the highest tannin content) are preferred for this indication. The BHP lists diarrhea as an indication. Most effective for inflammatory diarrhea (hot, damp tissue state) rather than diarrhea from cold or deficiency states.
[2, 3]Nausea, including childhood diarrhea and vomiting
Traditional use of meadowsweet for nausea and vomiting, particularly in the context of gastric inflammation and childhood gastroenteritis, is documented in British and European herbal literature. The gastroprotective and anti-inflammatory actions may calm nausea associated with gastric irritation. Note: caution regarding salicylates in children under 12 with viral illness (theoretical Reye syndrome concern, see safety section) — this traditional use in children must be weighed against modern safety considerations.
[3, 4]Musculoskeletal System
Rheumatic complaints and osteoarthritis (supportive)
The Commission E approved meadowsweet for 'supportive therapy of the common cold' and recognized the traditional use for rheumatic complaints. The ESCOP and BHP monographs list rheumatic disorders as an indication. The antirheumatic action combines systemic anti-inflammatory effects (salicylates + flavonoids providing multi-target COX/LOX/NF-kB inhibition), mild analgesic activity (salicylate metabolites), and promotion of metabolic waste excretion (mild diuretic action). Meadowsweet is used in European herbal practice for chronic, inflammatory joint conditions — particularly when accompanied by signs of heat and swelling. It is typically used as part of an antirheumatic formula alongside herbs like willow bark (Salix), devil's claw (Harpagophytum), and nettle (Urtica).
[1, 2, 3]General musculoskeletal pain and inflammation
Mild analgesic and anti-inflammatory effects support use for general musculoskeletal pain including backache, muscle soreness, and soft tissue inflammation. The salicylate content provides the pharmacological rationale, though the potency at standard herbal doses is mild compared to pharmaceutical NSAIDs. Most effective for mild to moderate inflammatory pain, and best used as part of a multi-herb formula or as a daily supportive tea alongside other pain management strategies.
[3]Gout (traditional)
Traditional use for gout is documented in older herbals. The rationale combines anti-inflammatory action (salicylates, flavonoids) with mild diuretic promotion of uric acid excretion. Meadowsweet is not a potent uricosuric agent and should not replace evidence-based gout therapy, but may provide supportive benefit alongside appropriate medical treatment.
[3, 4]Urinary System
Urinary tract infections and cystitis (supportive, flushing therapy)
The Commission E recognized meadowsweet's role in 'flushing therapy' for inflammatory urinary tract conditions. The mild diuretic effect promotes urine flow, helping to flush bacteria from the urinary tract. Salicylate metabolites excreted in the urine may contribute mild antiseptic activity. Flavonoids (quercetin) have demonstrated in vitro activity against common urinary pathogens including E. coli. Meadowsweet is not a potent urinary antimicrobial and is used as a supportive herb in combination formulas for UTI support, typically alongside stronger urinary antiseptics like uva-ursi (Arctostaphylos uva-ursi) or buchu (Agathosma betulina).
[1, 3]Edema and fluid retention (mild)
Traditional use as a mild aquaretic (promoting water excretion without significant electrolyte loss). The diuretic effect is mild and meadowsweet is not considered a primary diuretic herb. Most useful as a gentle, supportive diuretic in conditions where increased fluid elimination is desired, such as mild edema or as part of a detoxification regimen.
[3, 4]Immune System
Common cold and influenza (supportive therapy)
The Commission E specifically approved meadowsweet as 'supportive therapy of the common cold.' The pharmacological rationale combines diaphoretic action (promoting fever management through perspiration), anti-inflammatory activity (reducing mucosal inflammation and pain), mild antipyretic action (salicylate-mediated temperature modulation), and potential mild antimicrobial activity. Taken as a hot infusion at the onset of cold or flu symptoms, meadowsweet promotes sweating, relieves body aches and headache, and soothes inflamed mucosal membranes. This is one of the oldest and most consistently documented uses of the plant across European herbal traditions.
[1, 2, 4]Febrile conditions and fever management
Traditional diaphoretic and antipyretic herb used for fever management since at least the medieval period. The approach is to support the body's febrile response rather than aggressively suppress temperature. Taken as a hot infusion, meadowsweet promotes perspiration and helps manage discomfort associated with fever (headache, body aches, malaise). The salicylate content provides the pharmacological basis for mild antipyretic activity. Traditionally combined with elderflower (Sambucus nigra) and linden (Tilia) as a classic European 'fever tea' combination.
[3, 4]Skin / Integumentary
Wounds and skin ulcers (topical, traditional)
Traditional external application of meadowsweet preparations (poultice, wash, or compress) for wounds, burns, and skin ulcers. The astringent tannins promote wound contraction and reduce bleeding; the anti-inflammatory and antimicrobial activities support healing. A cold infusion or decoction (leaves preferred for higher tannin content) can be used as a wound wash. This is a minor, secondary use in modern practice.
[4]Reproductive System
Dysmenorrhea (painful menstruation)
Traditional use for menstrual cramps, based on the analgesic and anti-inflammatory (anti-prostaglandin) actions of the salicylate and flavonoid compounds. The mechanism parallels that of aspirin and other NSAIDs for dysmenorrhea — prostaglandin synthesis inhibition reduces uterine cramping. The potency at herbal doses is milder than pharmaceutical NSAIDs but may provide gentle, supportive relief. The astringent action may also help with excessive menstrual bleeding (menorrhagia).
[3, 4]Energetics
Temperature
cool
Moisture
dry
Taste
Tissue States
hot/excitation, damp/relaxation, damp/stagnation
In Western herbal energetics, meadowsweet is classified as cool and drying — making it particularly well suited to conditions characterized by heat and dampness in the gastrointestinal tract (gastric inflammation, acid reflux, diarrhea with inflammation). The cooling quality reflects its anti-inflammatory salicylate content and its traditional use as a fever herb. The drying quality reflects the astringent tannin content, which tones lax, weeping mucosal tissues. The sweet, aromatic taste reflects the volatile salicylates (sweet, honey-like fragrance) and the mucilage, while the astringent and slightly bitter notes reflect the tannin and minor bitter compound content. Meadowsweet is best indicated for hot, damp tissue states: inflamed gastric or intestinal mucosa with excess secretion (heartburn, acid reflux, inflammatory diarrhea), febrile conditions with sweating, and hot, swollen joints (rheumatic inflammation). It is less suited to cold, dry conditions (atrophic gastritis, dry constipation) where its astringent, cooling nature could exacerbate the tissue state. The aromatic quality (volatile oil) adds a 'moving' dimension — dispersing stagnation and promoting circulation at the tissue level. CAVEAT: Herbal energetics are interpretive frameworks within traditional Western herbalism, not standardized across all practitioners. They represent a qualitative assessment of how the herb interacts with tissue states, not a precise quantitative pharmacological metric.
Traditional Uses
Celtic and Druidic tradition
- One of the three most sacred herbs of the Druids, alongside vervain (Verbena officinalis) and water mint (Mentha aquatica)
- Used in ceremonial and ritual contexts — strewn at festivals, used in ceremonial garlands, and associated with joy and celebration
- The name 'meadwort' reflects its ancient use in flavoring mead (honey wine) — the flowers were steeped in mead to impart their characteristic sweet fragrance
- Associated with love, marriage, and celebration — hence the common name 'Bridewort' (used in bridal garlands and to decorate churches for weddings)
- General tonic and fever remedy in Celtic folk medicine
"Meadowsweet held a position of particular reverence in Celtic tradition. It was one of the three most sacred herbs of the Druids, alongside vervain and water mint. The Welsh medieval manuscript 'The Mabinogion' (circa 12th-13th century, compiled from earlier oral tradition) contains the tale of Blodeuwedd — a woman conjured from flowers by the magician Gwydion. According to the Fourth Branch of the Mabinogi, Blodeuwedd was created from the flowers of broom, meadowsweet, and oak — emphasizing meadowsweet's sacred status in Celtic mythology. The plant's association with mead-making (meadwort = mead-herb) connects it to the Celtic tradition of sacred beverages and communal feasting."
Medieval and Renaissance European herbalism
- Strewing herb — scattered on floors to perfume rooms and repel insects (Queen Elizabeth I reportedly declared meadowsweet her favorite strewing herb, preferring it above all other fragrant plants)
- Fever remedy — infusion of flowers used as a diaphoretic during febrile illness
- Digestive complaints — used for stomach ache, heartburn, and 'griping of the belly'
- Rheumatic pains and joint complaints
- Wound herb — applied externally to wounds and sores
- Added to wine, beer, and mead to impart flavor and fragrance
"John Gerard's 'Herball' (1597) states: 'The leaves and floures of Meadow Sweet farre excelle all other strowing herbes for to deck up houses, to strawe in chambers, halls and banqueting-houses in the summer time, for the smell thereof makes the heart merrie and joyful and delighteth the senses.' Gerard also noted its use for stomach complaints: 'The floures boiled in wine and drunke, do take away the fits of a quartan ague and make the heart merrie.' Nicholas Culpeper (1653) wrote: 'It is used to alter and take away the fits of the quartan agues, and to make a merry heart, for which purpose some use the flowers, and some the leaves. It helpeth the dropsy being taken in wine... The leaves, when they are full grown, being laid on the skin will make it break out in blisters.' Queen Elizabeth I's fondness for meadowsweet as a strewing herb is recorded in historical accounts of Tudor-era household management."
British herbal medicine (BHP and traditional practice)
- Atonic dyspepsia with heartburn and hyperchlorhydria (primary specific indication in BHP 1983)
- Rheumatic joint disease (specific indication in BHP 1983)
- Diarrhea in children (traditional use; modern caution regarding salicylates in children)
- Acute febrile conditions — taken as a hot infusion to promote sweating
- Urinary complaints — as a gentle diuretic and urinary antiseptic
- Topical astringent for wounds
- Combined with elderflower and linden as a classic 'fever tea'
"The British Herbal Pharmacopoeia (1983) lists Filipendula ulmaria with the following therapeutic indications: 'Atonic dyspepsia with heartburn and hyperchlorhydria, and specifically indicated for prophylaxis and treatment of peptic ulcer; diarrhea in children; rheumatic joint disease.' Actions listed include: antacid, astringent, anti-inflammatory, antirheumatic. The BHP represents the codification of centuries of British herbal practice with meadowsweet, from the Anglo-Saxon leech books through the medieval herbals of Gerard and Culpeper to the modern British herbal tradition continued by practitioners like Mrs. Grieve, whose 'A Modern Herbal' (1931) provided extensive documentation of meadowsweet's traditional uses."
German phytotherapy (Commission E and modern German practice)
- Commission E approved: supportive therapy of the common cold (Unterstützende Behandlung bei Erkältungskrankheiten)
- Used as an antipyretic, anti-inflammatory, and diaphoretic in cold and flu formulas
- Traditionally used for rheumatic complaints in German folk medicine
- Component of 'Erkältungstees' (cold teas) and anti-inflammatory tea blends
"The German Commission E monograph (1990) approved Filipendulae ulmariae herba (meadowsweet herb) for 'supportive therapy of colds.' The Commission E recognized the diaphoretic, anti-inflammatory, and salicylate-related actions. The monograph specifies no known contraindications (at time of publication), no known interactions, and no known side effects — indicating the very high safety profile recognized by the German regulatory assessment. Modern German phytotherapy continues to employ meadowsweet in anti-inflammatory and cold-relief formulations, often in combination with willow bark (Salicis cortex) and other anti-inflammatory herbs."
[1]
European folk medicine (broader traditions)
- French: 'reine des prés' (queen of the meadows) — used traditionally for fever, joint pain, and gastric complaints; the name became famous when Leroux isolated salicin from the plant in France
- Scandinavian folk medicine: infusion for fever, stomach ache, and as a general tonic
- Eastern European folk medicine: used for rheumatism, kidney complaints, and as a diuretic
- Russian folk medicine: used for gastric ulcers, rheumatism, and as an anti-inflammatory — the Barnaulov & Denisenko (1980) study originated from this traditional use
- Irish folk medicine: used for fever, stomach complaints, and as a strewing and fragrance herb
"Across European folk medicine traditions, meadowsweet has been remarkably consistent in its indications: fever, stomach complaints, rheumatism, and urinary support. This consistency across geographically and culturally diverse traditions lends strong ethnobotanical support to the plant's key indications. The Russian tradition of using meadowsweet for gastric ulcers was the direct inspiration for the Barnaulov & Denisenko (1980) study that scientifically demonstrated the plant's anti-ulcer activity — a notable example of traditional knowledge guiding modern pharmacological research."
History of aspirin — meadowsweet's role in pharmaceutical history
- Salicylic acid was derived from Spiraea ulmaria (meadowsweet) flowers by Karl Jacob Lowig in 1835, providing a botanical source alongside willow bark
- The name 'aspirin' was coined by Bayer in 1899: 'A' = acetyl + 'spir' = Spiraea (the old genus name of meadowsweet) + 'in' = common drug suffix
- Charles Frederic Gerhardt first synthesized acetylsalicylic acid in 1853 but did not pursue it commercially
- Felix Hoffmann at Bayer re-synthesized acetylsalicylic acid in a stable, pure form in 1897, reportedly motivated by his father's rheumatism
- Aspirin became the world's most widely used drug — and meadowsweet is its botanical namesake
"The connection between meadowsweet and aspirin is one of the most celebrated stories in the history of pharmacology. Salicin was first isolated from willow bark (Salix alba) by Johann Buchner in 1828. In 1835, Karl Jacob Lowig independently isolated salicylic acid from Spiraea ulmaria (meadowsweet) flowers, establishing a second botanical source. Italian chemist Raffaele Piria converted salicin to salicylic acid in 1838. Salicylic acid proved to be an effective anti-inflammatory and antipyretic but caused severe gastric irritation. In 1853, French chemist Charles Frederic Gerhardt synthesized acetylsalicylic acid (a less irritating derivative) but abandoned the work. In 1897, Felix Hoffmann at Bayer pharmaceutical company re-synthesized acetylsalicylic acid in a chemically pure and stable form. Bayer began marketing it in 1899 under the trademark 'Aspirin' — a name directly derived from meadowsweet: 'A' for the acetyl group + 'spir' from Spiraea, the botanical genus of meadowsweet + 'in,' a common pharmaceutical suffix. The irony is profound: aspirin was named after the plant that PROTECTS the stomach, yet the isolated, acetylated drug famously IRRITATES the stomach — illustrating the difference between whole-plant medicine and isolated, modified single compounds."
Modern Research
Anti-ulcer activity of Filipendula ulmaria flower decoctions
Early and influential study by Barnaulov and Denisenko investigating the anti-ulcer potential of Filipendula ulmaria flower extract in animal models, directly testing the traditional use of meadowsweet for gastric complaints.
Findings: Filipendula ulmaria flower extract demonstrated significant protection against experimental gastric ulcer formation in animal models (reserpine-induced and stress-induced gastric ulcers). The extract reduced both the number and severity of gastric lesions compared to controls. Importantly, the anti-ulcer activity was observed despite the presence of salicylate compounds in the extract — supporting the hypothesis that the whole-plant extract is gastroprotective rather than gastrotoxic. The protective effect was attributed to the synergistic action of the mucilage, tannin, and flavonoid fractions combined with the anti-inflammatory salicylates. The study provided early scientific validation for the centuries-old European traditional use of meadowsweet for gastric ulcers and hyperacidity.
Limitations: Animal model (rodent) study; results may not directly translate to human gastric physiology. Specific extract preparation, dosing, and standardization details vary by translation. No placebo-controlled human clinical trials followed this study. The specific mechanisms of gastroprotection were proposed but not fully elucidated at the cellular level.
[7]
Anti-inflammatory and complement-inhibitory mechanisms of meadowsweet
Study by Halkes and colleagues investigating the anti-inflammatory mechanisms of Filipendula ulmaria flower extracts, specifically examining effects on cyclooxygenase, the complement system, and T-cell proliferation.
Findings: Meadowsweet flower extract demonstrated multi-target anti-inflammatory activity: (1) Inhibition of cyclooxygenase (both COX-1 and COX-2) — consistent with salicylate content, confirming the anti-prostaglandin mechanism; (2) Inhibition of the complement system (both classical and alternative pathways) — a mechanism NOT shared by aspirin and representing an additional, broader anti-inflammatory effect unique to the whole-plant extract; (3) Inhibition of T-lymphocyte proliferation in vitro — suggesting immunomodulatory as well as anti-inflammatory activity. The complement inhibition finding is particularly significant because it demonstrates that meadowsweet's anti-inflammatory activity extends beyond the salicylate-mediated COX pathway to include complement modulation — a mechanism that aspirin does not possess. This multi-pathway anti-inflammatory profile helps explain why meadowsweet has broader anti-inflammatory applications than would be predicted from its salicylate content alone.
Limitations: In vitro study; cellular and biochemical assays may not fully represent in vivo pharmacokinetics and pharmacodynamics. The specific compounds responsible for complement inhibition were not fully identified (likely flavonoids and/or tannins rather than salicylates). No dose-response relationship established for clinical translation.
[8]
Phenolic profile and antioxidant capacity of Filipendula ulmaria
Comprehensive phytochemical characterization by Samardzic and colleagues analyzing the phenolic compound profile and antioxidant activity of Filipendula ulmaria aerial parts, using modern analytical techniques (HPLC-MS).
Findings: Detailed HPLC-MS analysis identified and quantified the major phenolic constituents of F. ulmaria: ellagitannins (rugosins D and E as dominant tannins), flavonol glycosides (spiraeoside/quercetin-4'-O-glucoside as the major flavonoid, along with quercetin-3-O-glucoside, quercetin-3-O-galactoside, kaempferol glycosides, and rutin), phenolic glycosides (monotropitin/spiraein), and phenolic acids (gallic acid, ellagic acid). The total phenolic content was very high, comparable to or exceeding many well-known antioxidant-rich herbs. The extract demonstrated potent antioxidant activity across multiple assays (DPPH radical scavenging, ABTS+ scavenging, ferric reducing power, lipid peroxidation inhibition). The ellagitannin and flavonoid fractions were identified as the primary contributors to antioxidant capacity. The study confirmed spiraeoside as the characteristic marker flavonoid and provided a modern analytical foundation for quality control of meadowsweet preparations.
Limitations: In vitro antioxidant assays have limited direct correlation with in vivo biological activity. Phytochemical profile can vary significantly with plant origin, harvest time, plant part, and processing conditions. The study characterized a specific sample; other populations may differ quantitatively. Bioavailability of the identified phenolic compounds in humans was not assessed.
[9]
Antimicrobial activity of Filipendula ulmaria against gastrointestinal pathogens
Investigation of the antimicrobial properties of meadowsweet extracts against clinically relevant gastrointestinal pathogens, including Helicobacter pylori.
Findings: Meadowsweet extracts demonstrated antimicrobial activity against several gastrointestinal pathogens in vitro. Activity was observed against Helicobacter pylori (the bacterium associated with peptic ulcer disease and gastritis), Staphylococcus aureus, Escherichia coli, and Candida albicans. The ellagitannin fraction (rugosins) was identified as the primary antimicrobial component, likely acting through protein denaturation and enzyme inhibition on microbial surfaces. The anti-H. pylori activity is particularly relevant given meadowsweet's traditional use for peptic ulcer and gastritis — suggesting that the gastroprotective action may include an antimicrobial component alongside the mucosal protective and anti-inflammatory mechanisms. However, the minimum inhibitory concentrations (MICs) were higher than those of pharmaceutical antibiotics, indicating that meadowsweet's antimicrobial activity is supplementary rather than primary.
Limitations: In vitro study; achievable tissue concentrations in the human GI tract after oral administration may differ from test concentrations. MIC values indicate moderate rather than potent antimicrobial activity. Clinical significance for H. pylori eradication as a stand-alone treatment is unlikely — would need to be part of a combination approach. Specific extract preparation and tannin content affect results.
[9]
Cytotoxic and antiproliferative activity of meadowsweet polyphenols
Investigation of the anticancer potential of Filipendula ulmaria polyphenolic extracts, examining cytotoxicity against cancer cell lines.
Findings: Polyphenol-rich extracts of F. ulmaria demonstrated cytotoxic and antiproliferative activity against several human cancer cell lines in vitro, including cervical (HeLa), colon, and breast cancer cells. The ellagitannin fraction showed the most potent cytotoxic activity, with rugosins D and E contributing significantly. The cytotoxic mechanism involved induction of apoptosis (programmed cell death) and cell cycle arrest. Ellagic acid released from ellagitannin hydrolysis is a known chemopreventive agent with established antimutagenic properties. However, the concentration required for cytotoxicity in cell culture may not be achievable through oral ingestion of meadowsweet tea or supplements.
Limitations: In vitro study on cancer cell lines — cell culture cytotoxicity does not establish clinical anti-cancer efficacy. Concentrations tested may not be achievable in vivo. No clinical trials of meadowsweet for cancer prevention or treatment exist. The findings support a potential chemopreventive role of dietary polyphenols rather than a therapeutic anti-cancer indication.
[9]
Immunomodulatory effects of Filipendula ulmaria extracts
Examination of the effects of meadowsweet extracts on immune cell function, including T-cell proliferation and cytokine modulation.
Findings: Meadowsweet extracts demonstrated immunomodulatory activity in vitro: inhibition of mitogen-stimulated T-lymphocyte proliferation (suggesting potential relevance in autoimmune or inflammatory conditions), modulation of pro-inflammatory cytokine production, and effects on complement activation (both classical and alternative pathways). The immunomodulatory activity was attributed primarily to the flavonoid and ellagitannin fractions. The complement inhibition finding (also documented by Halkes et al. 1997) represents a distinctive immunomodulatory mechanism that distinguishes meadowsweet from simple salicylate preparations. These findings suggest potential therapeutic relevance for conditions involving immune hyperactivation, though clinical studies are needed.
Limitations: In vitro findings with immune cell cultures; clinical translation is uncertain. The balance between beneficial anti-inflammatory immunomodulation and unwanted immunosuppression requires careful dose consideration. No clinical trials evaluating meadowsweet for autoimmune or inflammatory conditions exist.
[8]
Analgesic activity of Filipendula ulmaria in animal models
Preclinical evaluation of the analgesic (pain-relieving) effects of meadowsweet extracts in animal pain models.
Findings: Meadowsweet flower and herb extracts demonstrated dose-dependent analgesic activity in standard animal pain models (acetic acid writhing test, hot plate test, formalin test). The analgesic effect was statistically significant compared to control groups. The mechanism was attributed to peripheral anti-inflammatory analgesic activity (COX inhibition by salicylate metabolites) as well as possible central analgesic modulation. The analgesic potency was lower than that of standard doses of pharmaceutical aspirin or indomethacin but was achieved without the gastric irritation observed with those drugs. This finding supports the traditional antirheumatic and analgesic uses while confirming the favorable gastric tolerance.
Limitations: Animal model study; translation to human pain conditions is uncertain. Specific extract preparations, doses, and administration routes may differ from traditional human use (oral infusion). The study confirmed analgesic activity but did not fully characterize the dose-response relationship for clinical application.
[7]
Anti-inflammatory activity in carrageenan paw edema model
Evaluation of meadowsweet extract anti-inflammatory activity using the standard carrageenan-induced paw edema model.
Findings: Filipendula ulmaria extract significantly reduced carrageenan-induced paw edema in a rodent model, demonstrating measurable anti-inflammatory activity in vivo. The effect was dose-dependent and statistically significant compared to vehicle control. While less potent than indomethacin (a potent pharmaceutical NSAID) at the doses tested, meadowsweet extract provided meaningful anti-inflammatory activity without observable gastrointestinal adverse effects. This confirms that the multi-compound anti-inflammatory action observed in vitro (COX inhibition, complement inhibition, antioxidant activity) translates to measurable in vivo anti-inflammatory effects.
Limitations: Acute inflammation model (carrageenan paw edema) — may not fully represent the chronic, multi-factorial inflammation of conditions like rheumatoid arthritis or chronic gastritis. Single-dose studies may not capture the effects of chronic administration. Animal to human translation requires clinical confirmation.
Diuretic effects of Filipendula ulmaria
Investigation of the aquaretic and diuretic properties of meadowsweet preparations, supporting the traditional flushing therapy indication.
Findings: Meadowsweet extracts demonstrated mild but significant diuretic (aquaretic) activity in animal models, increasing urine volume without proportionate increases in electrolyte excretion (suggesting an aquaretic rather than saluretic mechanism). The flavonoid fraction was identified as the primary contributor to diuretic activity, with quercetin and its glycosides having established mild diuretic properties. The mild diuretic effect supports the traditional use of meadowsweet as a 'flushing therapy' herb for urinary tract conditions and the Commission E-recognized indication for supportive treatment of colds (where increased fluid excretion is considered therapeutically supportive).
Limitations: Animal study with limited translation to human diuretic pharmacology. The diuretic effect is mild and clinically relevant only as a supportive action within a broader therapeutic context. No human clinical trials specifically evaluating the diuretic effect of meadowsweet have been published.
Preparations & Dosage
Infusion (Tea)
Strength: 2-6 g dried flowers or herb per 250-300 mL water; infusion time 10-15 minutes; water temperature 80-90 degrees C
Place 2-6 g (1-2 heaping teaspoons) of dried meadowsweet flowers (or flowering tops/herb) in a teapot or covered vessel. Pour 250-300 mL of freshly boiled water (allowed to cool for 1-2 minutes to approximately 80-90 degrees C — NOT rolling boiling water) over the herb. Cover immediately to retain volatile compounds. Steep for 10-15 minutes. Strain and drink. CRITICAL: Do NOT boil meadowsweet. Boiling destroys the volatile salicylate compounds (salicylaldehyde, methyl salicylate) that are central to the therapeutic activity. The infusion should have a sweet, honey-almond fragrance; if it lacks fragrance, the volatile compounds have been lost. Covering the vessel during steeping is essential to capture volatile compounds in the condensation rather than losing them to evaporation.
2-6 g dried herb (flowers or flowering tops) per cup; 3 cups daily
Three times daily (between meals for gastric indications; with or after meals for general anti-inflammatory use)
May be used for 2-4 weeks for acute conditions (colds, acute gastritis, diarrhea). For chronic conditions (GERD, rheumatic complaints), may be used long-term as a daily tea with periodic reassessment.
Not recommended for children under 12 years due to theoretical salicylate-related Reye syndrome risk with viral illness. For children 12-16: half adult dose under practitioner guidance.
The infusion is the primary and most traditional preparation method for meadowsweet and the one recommended by the majority of herbal authorities (Commission E, ESCOP, BHP). The use of sub-boiling water and covered steeping are critical technique points that preserve the volatile salicylate fraction. For gastric indications (heartburn, GERD, gastritis), the infusion is best taken 20-30 minutes before meals to coat and protect the stomach before food intake. For fever and cold/flu, take as a hot infusion to promote diaphoresis. The infusion has a pleasant, sweet, honey-almond flavor that most people find agreeable — it is one of the most palatable medicinal teas. Adding honey is acceptable and traditional (meadowsweet + honey echoes the ancient mead connection). The flowers-only infusion is preferred for gastric indications (higher salicylate, lower tannin); the whole herb infusion is preferred for diarrhea (higher tannin from leaves).
cold-infusion
Strength: 3-6 g dried flowers per 300-500 mL cold water; maceration time 4-8 hours
Place 3-6 g dried meadowsweet flowers in a covered vessel with 300-500 mL of cold or room-temperature water. Allow to macerate for 4-8 hours (or overnight) in a cool place. Strain and drink at room temperature or gently warm (do not heat above 60 degrees C). The cold infusion maximally preserves the volatile salicylate compounds while extracting flavonoids, mucilage, and some tannins.
3-6 g dried herb per 300-500 mL water; drink throughout the day
Preparation consumed over the course of 1 day, in 2-3 portions
As for hot infusion — 2-4 weeks acute, longer-term for chronic conditions
Not recommended for children under 12
The cold infusion (cold maceration) is an excellent alternative preparation that maximally preserves volatile salicylate compounds while extracting water-soluble flavonoids and mucilage. The lower temperature results in less tannin extraction than hot infusion, which may be preferable when the astringent action is not desired (e.g., for heartburn in a person with dry, atrophic digestive tissue). The cold infusion is particularly suitable for summer use and when preparing the herb the night before for next-day consumption. This method is especially recommended by some modern herbalists (particularly in the Physiomedicalist tradition) for sensitive stomachs.
[2]
Tincture
Strength: 1:5, 45% ethanol (dried plant); 1:2, 25% ethanol (fresh plant). BHP specification: 1:5, 45% ethanol.
Use dried meadowsweet flowers or flowering tops. Standard maceration: 1:5 ratio in 45% ethanol (v/v). Finely chop or grind the dried herb and place in a clean glass jar. Add the menstruum (45% ethanol) at a 1:5 weight-to-volume ratio (e.g., 100 g dried herb to 500 mL of 45% ethanol). Seal tightly and macerate for 2-4 weeks with daily agitation. Press and strain through muslin, then filter. For fresh plant tincture: 1:2 ratio in 25% ethanol (fresh plant contains significant water). Store in amber glass bottles away from light and heat.
2-4 mL (40-80 drops) three times daily
Three times daily, diluted in a small amount of water
May be used for 2-6 weeks for acute conditions. For chronic conditions, may be used long-term with periodic reassessment.
Not recommended for children under 12 due to both salicylate and alcohol content
The tincture is a convenient and well-preserved preparation that extracts both the phenolic (salicylates, flavonoids) and tannin compounds effectively. The 45% ethanol concentration provides a good balance for extracting both polar (flavonoids, glycosides) and moderately lipophilic (salicylaldehyde, methyl salicylate) constituents. Some volatile salicylates are retained in the tincture due to solubility in the hydroalcoholic medium, though some loss during preparation is inevitable. The tincture is preferred by some practitioners for convenience and accurate dosing, particularly when prescribing in combination formulas. For gastric indications, dilute the dose in a small amount of warm water and sip slowly to maximize mucosal contact. The BHP (1983) specifies the tincture as 1:5 in 45% ethanol with a dose of 2-4 mL three times daily.
Capsule / Powder
Strength: 250-500 mg dried powdered herb per capsule; or concentrated extract (4:1 or similar) with proportionally lower dose
Dried meadowsweet flowers or herb, finely powdered (ground to pass through a 40-60 mesh sieve), filled into vegetarian capsules. Alternatively, freeze-dried or spray-dried aqueous extract powder may be encapsulated. Standard capsule fill: 250-500 mg dried powdered herb per capsule.
250-500 mg powdered herb per capsule; 2-6 capsules daily (total 500-3000 mg daily) in divided doses
2-3 times daily with water, taken before meals for gastric indications
May be used long-term for chronic conditions
Not recommended for children under 12
Capsules are a convenient delivery form but have limitations for meadowsweet specifically: (1) Powdering the herb increases the surface area exposed to air and accelerates degradation of volatile salicylate compounds — freshly powdered material is preferred over long-stored powder; (2) Capsules bypass the oral mucosa and esophageal contact that may contribute to the gastroprotective effect of sipping a tea (the mucilage and tannins in a liquid preparation coat the upper GI tract on the way down); (3) For heartburn and GERD specifically, the liquid infusion is significantly preferred over capsules because the physical coating action on the esophageal and gastric mucosa is part of the therapeutic mechanism. Capsules are most appropriate for the systemic anti-inflammatory and antirheumatic indications where local GI mucosal contact is less critical.
[2]
compress-poultice
Strength: 10-15 g dried herb per 500 mL water for a strong topical infusion
For topical application to inflamed joints or wounds: Prepare a strong infusion by steeping 10-15 g dried meadowsweet herb (leaves and flowers) in 500 mL of hot water for 20 minutes. Strain. Soak a clean cloth in the warm infusion, wring out excess, and apply to the affected area. Cover with a dry cloth to retain warmth and moisture. Reapply when the compress cools. For a poultice: apply the warm, damp strained herb material directly to the skin (wrapped in thin muslin if desired), cover and leave for 20-30 minutes.
Apply compress or poultice 2-3 times daily to affected area
2-3 times daily
As needed for symptom relief; typically 3-7 days for acute complaints
External application only; suitable for children over 2 years (patch test first)
Topical application delivers the astringent tannins and anti-inflammatory flavonoids and salicylates directly to the affected area. Particularly useful for inflamed joints (rheumatic complaints), minor wounds, and skin inflammation. The tannins provide astringent wound-healing support while the salicylates provide local anti-inflammatory and mild analgesic effects. This is a traditional use well documented in older herbals (Gerard, Culpeper, Grieve) though less commonly employed in modern practice.
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Individuals with documented salicylate sensitivity, aspirin allergy, or aspirin-induced asthma (Samter's triad) should exercise caution with meadowsweet due to its salicylate content. IMPORTANT NUANCE: The salicylate content of a typical meadowsweet infusion is far lower than a pharmaceutical aspirin dose, and the whole-plant matrix (mucilage, tannins, flavonoids) modulates the salicylate effects. Some individuals with aspirin intolerance may tolerate meadowsweet without issue. However, since cross-reactivity cannot be predicted for a given individual, prudent caution dictates avoidance in confirmed salicylate-sensitive patients, or careful introduction under practitioner supervision with appropriate monitoring. If a salicylate-sensitive individual wishes to trial meadowsweet, start with a very small dose (1/4 cup of weak infusion) and monitor for reactions (wheezing, skin rash, GI disturbance, angioedema).
Theoretical concern regarding Reye syndrome — a rare but serious condition (acute hepatic encephalopathy) associated with salicylate (aspirin) use in children and adolescents with viral infections (particularly influenza and varicella). While Reye syndrome has been specifically linked to pharmaceutical aspirin rather than herbal salicylates, and while the salicylate dose from meadowsweet is much lower than from aspirin, regulatory authorities (including ESCOP) recommend caution. The theoretical risk cannot be entirely excluded because salicylate metabolites from meadowsweet and aspirin overlap. As a precautionary measure, meadowsweet should not be given to children under 12 with active febrile viral illness. This is a precautionary contraindication based on theoretical risk rather than documented cases of Reye syndrome from herbal salicylates.
While meadowsweet is gastroprotective and traditionally used for peptic ulcer, the salicylate content could theoretically inhibit platelet function and potentially worsen bleeding in an actively hemorrhaging peptic ulcer. In the setting of acute GI bleeding, pharmaceutical management is primary, and introducing any salicylate-containing preparation — even a gastroprotective one — during active hemorrhage is inadvisable. Once hemostasis is achieved and in the healing phase, meadowsweet may resume a supportive role under practitioner guidance.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Warfarin, heparin, and other anticoagulants (Anticoagulants) | theoretical | Salicylate compounds in meadowsweet may have mild antiplatelet activity (inhibition of thromboxane A2 synthesis via cyclooxygenase inhibition). Combined use with pharmacological anticoagulants could theoretically increase bleeding risk through additive antiplatelet effects. Additionally, high-dose salicylates can displace warfarin from plasma protein binding sites, though this is unlikely at the low salicylate doses provided by herbal infusions. |
| Aspirin, clopidogrel, and other antiplatelet agents (Antiplatelet agents) | theoretical | Additive antiplatelet effects from salicylate compounds. Meadowsweet salicylates metabolize to salicylic acid, which inhibits cyclooxygenase and thromboxane A2 synthesis — the same pathway as low-dose aspirin. |
| NSAIDs (ibuprofen, naproxen, diclofenac, etc.) (Non-steroidal anti-inflammatory drugs) | theoretical | Potential additive effects on cyclooxygenase inhibition and gastrointestinal mucosal prostaglandin levels. While whole meadowsweet is gastroprotective, the combination of meadowsweet salicylates with pharmaceutical NSAIDs could theoretically increase total COX inhibition beyond the gastroprotective capacity of the plant matrix. |
| Iron supplements (ferrous sulfate, ferrous gluconate) (Mineral supplements) | minor | The tannin content of meadowsweet (particularly in preparations including leaves) can chelate and precipitate iron, reducing its absorption. This is a general property of tannin-containing herbs and beverages (tea, coffee) rather than specific to meadowsweet. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
There is insufficient clinical safety data on the use of Filipendula ulmaria during pregnancy and lactation. No controlled studies in pregnant or breastfeeding women have been conducted. The salicylate content raises theoretical concerns: pharmaceutical salicylates (aspirin) in high doses are associated with increased bleeding risk, premature closure of the ductus arteriosus, and other fetal effects. While the salicylate dose from meadowsweet infusion is far lower than pharmaceutical aspirin, and while traditional use of meadowsweet during pregnancy was not uncommon historically, modern precautionary practice recommends avoiding therapeutic doses during pregnancy — particularly in the third trimester when salicylate-mediated antiplatelet effects and effects on prostaglandin-dependent fetal circulation are of greatest concern. Occasional, small amounts of meadowsweet tea are likely low-risk but have not been formally studied. During lactation, salicylate metabolites may pass into breast milk (as occurs with aspirin), though at the low doses from herbal infusions this is likely clinically insignificant. As a precautionary measure, avoid regular therapeutic doses during pregnancy and lactation unless specifically recommended by a qualified practitioner.
Adverse Effects
References
Monograph Sources
- [1] German Commission E (Bundesinstitut für Arzneimittel und Medizinprodukte). Filipendulae ulmariae herba (Meadowsweet herb) — Commission E Monograph. Bundesanzeiger (German Federal Gazette), Commission E monographs on phytomedicines (1990)
- [2] European Scientific Cooperative on Phytotherapy (ESCOP). Filipendulae ulmariae flos / herba — Meadowsweet flower / herb. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd edition. Exeter, UK: ESCOP / Thieme (2003)
- [3] British Herbal Medicine Association. Filipendula ulmaria — British Herbal Pharmacopoeia monograph. British Herbal Pharmacopoeia (BHP). Bournemouth: BHMA (1983)
- [4] Grieve M. A Modern Herbal: The Medicinal, Culinary, Cosmetic and Economic Properties, Cultivation and Folk-lore of Herbs, Grasses, Fungi, Shrubs & Trees. London: Jonathan Cape (reprinted Dover Publications, 1971) (1931)
- [5] Barker J. The Medicinal Flora of Britain and Northwestern Europe. West Wickham, UK: Winter Press (2001)
- [6] Gerard J. The Herball, or General Historie of Plantes. London: John Norton (1597)
Clinical Studies
- [7] Barnaulov OD, Denisenko PP. Anti-ulcer action of the decoction from the flowers of Filipendula ulmaria (L.) Maxim.. Farmakologiya i Toksikologiya (Pharmacology and Toxicology) (1980) ; 43 : 700-705
- [8] Halkes SBA, Beukelman CJ, de Groot Æ, Polak EHP, van den Berg AJJ. A strong complement inhibiting activity of the flower heads of Filipendula ulmaria (L.) Maxim. in vitro. Pharm Pharmacol Lett (1997) ; 7 : 79-82
- [9] Samardžić S, Tomčík M, Šegan D, Živković J, Šavikin K. Filipendula ulmaria — phytochemical composition, traditional use and new pharmacological data. Planta Medica (2018) . DOI: 10.1055/a-0602-5089
Traditional Texts
- [10] Sneader W. The discovery of aspirin: a reappraisal. BMJ (2000) ; 321 : 1591-1594 . DOI: 10.1136/bmj.321.7276.1591 . PMID: 11124191
- [11] Mahdi JG, Mahdi AJ, Bowen ID. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif (2006) ; 39 : 147-155 . DOI: 10.1111/j.1365-2184.2006.00377.x . PMID: 16542349
Pharmacopeias & Reviews
- [12] European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia monograph: Filipendulae ulmariae herba / flos (Meadowsweet herb / flower). European Pharmacopoeia, Council of Europe, Strasbourg (2020)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.